Figure 1 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer

https://doi.org/10.1158/0008-5472.28329149

figure

posted on 2025-02-01, 19:20 authored by Abigail Shea, Yaniv Eyal-Lubling, Daniel Guerrero-Romero, Raquel Manzano Garcia, Wendy Greenwood, Martin O’Reilly, Dimitra Georgopoulou, Maurizio Callari, Giulia Lerda, Sophia Wix, Agnese Giovannetti, Riccardo Masina, Elham Esmaeilishirazifard, Wei Cope, Alistair G. Martin, Ai Nagano, Lisa Young, Steven Kupczak, Yi Cheng, Helen Bardwell, Elena Provenzano, Justine Kane, Jonny Lay, Louise Grybowicz, Karen McAdam, Carlos Caldas, Jean Abraham, Oscar M. Rueda, Alejandra Bruna

A preclinical platform of TNBC PDTXs. A, Clinical treatment and responses of the patient cohort from which the PDTX models used in this study were derived. B, Experimental framework of the coclinical trial. C, Top, correlation plots comparing GSEA enrichment scores (Hallmark and C6 gene sets) for models 1006, 1040, 1022, and 1141. Bottom, correlation plots comparing mutation VAFs for model 1006. Correlation was calculated between passages, sister mice, and multiple regions of the same tumor using Spearman correlation.

Funding

Cancer Research UK (CRUK)

Cancer Research UK Cambridge Institute, University of Cambridge (CRUK CI)

HORIZON EUROPE European Research Council (ERC)

NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC)

Medical Research Council (MRC)

HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA)

Institute of Cancer Research (ICR)

History

Related Materials

1.
DOI - Is supplement to Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer

ARTICLE ABSTRACT

The intertumor and intratumor heterogeneity of triple-negative breast cancers, which is reflected in diverse drug responses, interplays with tumor evolution. In this study, we developed a preclinical experimental and analytical framework using patient-derived tumor xenografts (PDTX) from patients with treatment-naïve triple-negative breast cancers to test their predictive value in personalized cancer treatment approaches. Patients and their matched PDTXs exhibited concordant drug responses to neoadjuvant therapy using two trial designs and dosing schedules. This platform enabled analysis of nongenetic mechanisms involved in relapse dynamics. Treatment resulted in permanent phenotypic changes, with functional and therapeutic consequences. High-throughput drug screening methods in ex vivo PDTX cells revealed patient-specific drug response changes dependent on first-line therapy. This was validated in vivo, as exemplified by a change in olaparib sensitivity in tumors previously treated with clinically relevant cycles of standard-of-care chemotherapy. In summary, PDTXs provide a robust tool to test patient drug responses and therapeutic regimens and to model evolutionary trajectories. However, high intermodel variability and permanent nongenomic transcriptional changes constrain their use for personalized cancer therapy. This work highlights important considerations associated with preclinical drug response modeling and potential uses of the platform to identify efficacious and preferential sequential therapeutic regimens.Significance: Patient-derived tumor xenografts from treatment-naïve breast cancer samples can predict patient drug responses and model treatment-induced phenotypic and functional evolution, making them valuable preclinical tools.